Amenamevir is a novel anti-herpesvirus drug that exerts its therapeutic effect by inhibiting viral DNA replication.

I. What is Amenamevir?

1. Drug Category and Indications

(1) Amenamevir belongs to anti-herpesvirus agents, mainly used for the treatment of herpes zoster and recurrent herpes simplex (including oral herpes and genital herpes) in adults.

(2) It is a prescription drug and must be used under the guidance of a doctor.

2. Dosage Forms and Specifications

(1) This product is a pale yellow film-coated tablet, each containing 200 mg of amenamevir.

(2) Common packaging includes 6 tablets or 14 tablets in PTP blister packs; the tablet should be taken after being removed from the blister pack.

3. Storage Conditions

(1) Store at room temperature, avoid high temperature and humidity, with a shelf life of 48 months.

(2) Keep out of the reach of children to prevent accidental ingestion.

II. Mechanism of Action and Drug Interactions

1. Mechanism of Action

(1) Amenamevir inhibits the helicase-primase complex of herpesviruses, thereby blocking viral DNA replication.

(2) It has inhibitory effects on varicella-zoster virus, herpes simplex virus type 1 and type 2, and remains active against acyclovir-low-sensitivity strains.

2. Drug Interactions

2.1 Contraindicated Combinations

Rifampicin is contraindicated for concomitant use with amenamevir, as rifampicin can significantly reduce the blood concentration of amenamevir, leading to a decrease in therapeutic efficacy.

2.2 Combinations Requiring Caution

(1) CYP3A inhibitors (e.g., clarithromycin, ritonavir): May increase the blood concentration of amenamevir and raise the risk of adverse reactions.

(2) CYP3A inducers (e.g., carbamazepine, phenobarbital): May reduce the blood concentration of amenamevir and weaken its therapeutic effect.

(3) CYP3A substrate drugs (e.g., midazolam): Amenamevir may accelerate the metabolism of these drugs and reduce their efficacy.

(4) Ciclosporin: Concomitant use may decrease the blood concentration of amenamevir, requiring close monitoring.

3. Food Interactions

(1) St. John's Wort: Can induce CYP3A, reduce the blood concentration of amenamevir, and should be avoided during medication.

(2) Grapefruit juice: May lower the blood concentration of amenamevir, and its consumption is not recommended.

III. Management of Missed and Overdoses

1. Management of Missed Doses

1.1 Herpes Zoster (Once-daily Administration)

(1) If a dose is missed, take it as soon as possible; if it is close to the time for the next dose, skip the missed dose and take the next dose as scheduled.

(2) Do not take a double dose at one time.

1.2 Recurrent Herpes Simplex (Single-dose Administration)

(1) If the dose is forgotten within 6 hours after the onset of initial symptoms, take it as soon as possible.

(2) If more than 6 hours have passed or the rash has appeared, do not take the missed dose; wait for the next recurrence and consult a doctor before using the drug.

2. Management of Overdoses

(1) In case of accidental overdose, discontinue the drug immediately and seek medical attention.

(2) This product can be partially cleared by hemodialysis, but hemodialysis should not be performed without medical guidance.

(3) When seeking medical help, inform the doctor of the dosage and time of ingestion, and the doctor will evaluate and take corresponding measures.

3. Medication Safety Tips

(1) Patients with recurrent herpes simplex should only prepare a single dose for each recurrence to avoid hoarding drugs.

(2) Before taking the drug, confirm the ability to accurately identify initial symptoms and use the drug within the specified time.

(3) Pregnant and lactating women should not take the drug on their own in case of recurrence and should seek medical attention in a timely manner.